Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 two-part, randomized, double-blind, placebo-controlled dose-escalation SAD/MAD study of VTX-958

Next Previous
X
Search
Trial Profile

Phase 1 two-part, randomized, double-blind, placebo-controlled dose-escalation SAD/MAD study of VTX-958

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VTX-958 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 15 Aug 2022 Results published in the Ventyx Biosciences Media Release.
    • 11 Aug 2022 According to a Ventyx Biosciences media release, the company to host a conference call and webcast to discuss topline results from this study on 15 Aug, 2022.
    • 23 Mar 2022 According to a Ventyx Biosciences media release, the company expect to complete dosing of the last subject in the second quarter of 2022. Topline data from this trial expected in the early Q3 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top